Cidara and hVIVO report positive results in flu prevention study
30th June 2025 Uncategorised 0New data show strong efficacy of CD388 in phase 2b trial More: Cidara and hVIVO report positive results in flu prevention study Source: News
read more
New data show strong efficacy of CD388 in phase 2b trial More: Cidara and hVIVO report positive results in flu prevention study Source: News
read moreWith a first-in-class approval in China, Eli Lilly’s GLP-1 development engine has delivered yet again on the obesity front—although local biopharma outfit Innovent Biologics will be the one to reap the rewards in the near term. More: With China approval,
read moreAlongside its development of artificial intelligence-powered software to analyze huge amounts of genomic, imaging and other healthcare data, Sophia Genetics is now turning to a new medium to explain that work to the masses. More: Sophia Genetics launches podcast to
read moreUCB’s Fintepla has been approved to treat seizures associated with two epilepsy disorders and now has posted data that could pave the way for its use in another epilepsy condition. A phase 3 trial of Fintepla treating patients with the
read moreThe FDA has removed the REMS requirements for currently approved BCMA- and CD19-directed CAR-T therapies and reduced certain post-infusion restrictions. More: FDA removes CAR-T access barriers in move set to boost cancer immunotherapy uptake Source: fierce
read moreWhile concerns over pricing and access to Novo’s Wegovy and Lilly’s Zepbound persist, especially given the sheer number of people who received replicated versions while the meds were in shortage, indulging compounders who continue to sell cheaper copycats en masse
read more© 1994 - 2026 B.M. Pharmaceuticals